Estrella Immunopharma’s (ESLA) “Buy” Rating Reaffirmed at D. Boral Capital

Estrella Immunopharma (NASDAQ:ESLA)‘s stock had its “buy” rating restated by investment analysts at D. Boral Capital in a research report issued on Monday,Benzinga reports. They presently have a $16.00 price objective on the stock.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Estrella Immunopharma in a research report on Friday. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $16.00.

Estrella Immunopharma Stock Performance

Shares of ESLA stock traded up $0.24 during mid-day trading on Monday, hitting $2.66. 587,566 shares of the stock were exchanged, compared to its average volume of 132,180. The stock’s fifty day simple moving average is $1.42 and its two-hundred day simple moving average is $1.11. Estrella Immunopharma has a 12-month low of $0.70 and a 12-month high of $2.90. The stock has a market capitalization of $98.60 million, a price-to-earnings ratio of -8.95 and a beta of 0.39.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.